From June 5^th, 2020, patients suffering from non-small cell lung cancer who are prescribed Tagrisso (Osimertinib) medication will be offered financial support for a follow-up drug cycle at Hy Vong Cancer Care Centre, FV Hospital. This support programme will be available to the patient after they have undergone a complete cycle of the drug and until they stop treatment as directed by the doctor or when they decide to stop participating in the programme.

Specifically, the financial support is partial support for the cost of Tagrisso (Osimertinib) for patients who have locally advanced or metastatic non-small cell lung cancer with positive metastases with positive EGFR/EGFR T790M. This policy was approved by the Ministry of Health on April 17^th, 2020 and has been applied to a small number of hospitals in Vietnam, including the Hy Vong Cancer Care Centre.

Tagrisso contributes to the effectiveness of treatment, helping patients live longer

Tagrisso (Osimertinib) is a new generation drug from the manufacturer AstraZeneca AB, from Sweden. The product has been licensed for circulation in the US since 2015, and in Vietnam since 2018. It is currently being distributed by the Central Pharmaceutical Joint Stock Company 2 (Phytopharma).

The Tagrisso drug comes in the form of film-coated tablets, in a packet of three blisters, each with 10 tablets. Depending on the doctor’s prescription, patients may be given a dose of either 40mg or 80mg. Tagrisso has been identified by experts as a targeted drug for patients with locally advanced or metastatic non-small cell lung cancer with certain types of abnormal EGFR genes or EGFR T790M-positive.

From clinical studies, patients with non-small cell lung cancer using Tagrisso have a better life expectancy with improved disease-free progression than those using other targeted therapies or chemotherapy drugs.

Benefits of registering for the Tagrisso support programme at Hy Vong Cancer Care Centre

Over the years, the Hy Vong Cancer Care Centre has continuously developed and improved the quality of effective healthcare services for cancer patients. The centre is constantly updating and applying the most advanced methods and techniques in the world to help optimize therapeutic effects. Examples of such methods include: VMAT radiotherapy technology, conservative surgery, immunotherapy, targeted therapy, among others.

In addition, FV’s team of doctors and nurses is both highly experienced, and dedicated in the caring and understanding of each case. Each patient is consulted on a case by case basis, having a treatment regimen which is specifically suitable to their condition, stage of their disease, medical history etc.. Such treatment is administered in comfort with state-of-the-art facilities to help patients improve their physical and mental health, keeping them as strong as possible to fight their condition.

How to receive financial support when receiving Tagrisso?

The programme is applicable to patients who are 18 years of age or older, with or without health insurance, who are diagnosed with locally advanced or metastatic non-small cell lung cancer with EGFR mutation or positive for EGFR T790M (including patients undergoing treatment or newly diagnosed without treatment), and are prescribed Tagrisso medication.

To apply, patients need to register at the Hy Vong Cancer Care Centre, FV Hospital from June 5^th, 2020 to December 4^th, 2021. The financial support is applied once the patient purchases and completes a cycle of Tagrisso, i.e. 30 days. There will then be financial support for the subsequent cycle of drugs, amounting to a packet of Tagrisso which includes 30 pills. Patients will receive Tagrisso medication until their treatment is discontinued as prescribed by the doctor or they themselves decide to stop participating in the programme.

Please note, all financially supported medication has been labelled – Support – not for sale.

For more information on Tagrisso medication financial support for patients with non-small cell lung cancer and the Hy Vong Cancer Care Centre, please contact: (028) 5411 3440 or (028) 5411 3333 – Extension: 5000.